通过细胞外囊对激活的JAK-STAT通路进行抗卵巢癌的治疗
Kazuhiro Suzuki1, Akira Yokoi2,3,4, Kosuke Yoshida1,5
1Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Communications biology
|August 29, 2025
概括
抗性卵巢癌 (PROC) 是一个重大挑战. 这项研究发现,细胞外囊泡 (EVs) 通过激活JAK/STAT通路来促进PROC,这表明JAK抑制剂是潜在的治疗方法.
科学领域:
- 癌症学
- 分子生物学
- 癌症研究
背景情况:
- 抗性卵巢癌 (PROC) 是一个严重的未满足的临床需求,其分子基础尚不清楚.
- 细胞外囊泡 (EV) 是瘤微环境中的细胞间通信的关键媒介.
- 卵巢癌中的液为研究PROC机制提供了独特的环境.
研究的目的:
- 阐明驱动PROC的分子机制,特别关注瘤环境的作用.
- 确定在卵巢癌中克服抗性的新疗法目标.
主要方法:
- 临床卵巢癌样本的多转录组分析.
- 在患者中,免疫组织化学与JAK1表达与反应相关.
- 在PROC模型中对JAK抑制剂进行了体外和体内疗效研究.
- 小RNA测序以识别EV中的微RNA.
主要成果:
- PROC的特征是激活的Janus激酶 (JAK) /信号转换器和转录激活器 (STAT) 途径,由癌细胞中的高JAK1表达体现.
- 增加的JAK1表达与患者对化疗的反应有负相关性.
- 雅克抑制剂对PROC细胞系和异种移植具有有效性,与制剂具有协同作用.
- 发现在miR135a-5p中丰富的激活的腹膜间皮细胞衍生的EV增强了JAK表达,并赋予了抗癌细胞.
结论:
- 在卵巢癌中,细胞外囊泡在调节敏感性方面起着至关重要的作用.
- 针对JAK/STAT途径是一个有前途的治疗策略来克服PROC.
- 通过EVs传递的miR135a-5p通过上调JAK表达来促进抗性.
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:22PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K